Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Apr 16.

Published in final edited form as: Br J Haematol. 2017 Mar 24;177(2):263–270. doi: 10.1111/bjh.14541

Fig 3 — (A) Disease-specific survival by subtype

SLL, small lymphocytic lymphoma

(B)Cumulative probability of second malignancy by treatment

FND→R, sequential fludarabine, mitoxantrone, dexamethasone followed by rituximab; RFND, concurrent fludarabine, mitoxantrone, dexamethasone and rituximab.

Fig 3 — (A) Disease-specific survival by subtype

SLL, small lymphocytic lymphoma

(B)Cumulative probability of second malignancy by treatment

FND→R, sequential fludarabine, mitoxantrone, dexamethasone followed by rituximab; RFND, concurrent fludarabine, mitoxantrone, dexamethasone and rituximab.